Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Country Data for Action: The MenAfriNet Experience in Strengthening Meningitis Surveillance in Africa.

Novak RT, Moïsi JC, Tall H, Preziosi MP, Hadler SC, Messonnier NE, Mihigo R; MenAfriNet Consortium .

J Infect Dis. 2019 Oct 31;220(Supplement_4):S137-S139. doi: 10.1093/infdis/jiz347. No abstract available.

PMID:
31671440
2.

Progress in Vaccine-Preventable and Respiratory Infectious Diseases-First 10 Years of the CDC National Center for Immunization and Respiratory Diseases, 2006-2015.

Schuchat A, Anderson LJ, Rodewald LE, Cox NJ, Hajjeh R, Pallansch MA, Messonnier NE, Jernigan DB, Wharton M.

Emerg Infect Dis. 2018 Jul;24(7):1178-1187. doi: 10.3201/eid2407.171699.

3.

Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Liang JL, Tiwari T, Moro P, Messonnier NE, Reingold A, Sawyer M, Clark TA.

MMWR Recomm Rep. 2018 Apr 27;67(2):1-44. doi: 10.15585/mmwr.rr6702a1.

4.

Effectiveness and Duration of Protection of One Dose of a Meningococcal Conjugate Vaccine.

Cohn AC, MacNeil JR, Harrison LH, Lynfield R, Reingold A, Schaffner W, Zell ER, Plikaytis B, Wang X, Messonnier NE; Active Bacterial Core Surveillance (ABCs) Team and MeningNet Surveillance Partners.

Pediatrics. 2017 Feb;139(2). pii: e20162193. doi: 10.1542/peds.2016-2193.

5.

Population-Based Surveillance of Neisseria meningitidis Antimicrobial Resistance in the United States.

Harcourt BH, Anderson RD, Wu HM, Cohn AC, MacNeil JR, Taylor TH, Wang X, Clark TA, Messonnier NE, Mayer LW.

Open Forum Infect Dis. 2015 Aug 13;2(3):ofv117. doi: 10.1093/ofid/ofv117. eCollection 2015 Sep.

6.

Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic.

Acosta AM, DeBolt C, Tasslimi A, Lewis M, Stewart LK, Misegades LK, Messonnier NE, Clark TA, Martin SW, Patel M.

Pediatrics. 2015 Jun;135(6):981-9. doi: 10.1542/peds.2014-3358. Epub 2015 May 4.

7.

Changes in the Population Structure of Invasive Neisseria meningitidis in the United States After Quadrivalent Meningococcal Conjugate Vaccine Licensure.

Wang X, Shutt KA, Vuong JT, Cohn A, MacNeil J, Schmink S, Plikaytis B, Messonnier NE, Harrison LH, Clark TA, Mayer LW.

J Infect Dis. 2015 Jun 15;211(12):1887-94. doi: 10.1093/infdis/jiu842. Epub 2015 Jan 2.

PMID:
25556253
8.

Meningococcal carriage among Georgia and Maryland high school students.

Harrison LH, Shutt KA, Arnold KE, Stern EJ, Pondo T, Kiehlbauch JA, Myers RA, Hollick RA, Schmink S, Vello M, Stephens DS, Messonnier NE, Mayer LW, Clark TA.

J Infect Dis. 2015 Jun 1;211(11):1761-8. doi: 10.1093/infdis/jiu679. Epub 2014 Dec 11.

9.

Persistence of serogroup C antibody responses following quadrivalent meningococcal conjugate vaccination in United States military personnel.

Patel M, Romero-Steiner S, Broderick MP, Thomas CG, Plikaytis BD, Schmidt DS, Johnson SE, Milton AS, Carlone GM, Clark TA, Messonnier NE, Cohn AC, Faix DJ.

Vaccine. 2014 Jun 24;32(30):3805-9. doi: 10.1016/j.vaccine.2014.05.001. Epub 2014 May 14.

10.

Neisseria meningitidis serogroup W, Burkina Faso, 2012.

MacNeil JR, Medah I, Koussoubé D, Novak RT, Cohn AC, Diomandé FV, Yelbeogo D, Kambou JL, Tarbangdo TF, Ouédraogo-Traoré R, Sangaré L, Hatcher C, Vuong J, Mayer LW, Djingarey MH, Clark TA, Messonnier NE.

Emerg Infect Dis. 2014 Mar;20(3):394-9. doi: 10.3201/eid2003.131407.

11.

Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women.

Meaney-Delman D, Zotti ME, Creanga AA, Misegades LK, Wako E, Treadwell TA, Messonnier NE, Jamieson DJ; Workgroup on Anthrax in Pregnant and Postpartum Women.

Emerg Infect Dis. 2014 Feb;20(2). doi: 10.3201/eid2002.130611.

12.

Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults.

Hendricks KA, Wright ME, Shadomy SV, Bradley JS, Morrow MG, Pavia AT, Rubinstein E, Holty JE, Messonnier NE, Smith TL, Pesik N, Treadwell TA, Bower WA; Workgroup on Anthrax Clinical Guidelines.

Emerg Infect Dis. 2014 Feb;20(2). doi: 10.3201/eid2002.130687.

13.

Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial.

Wright JG, Plikaytis BD, Rose CE, Parker SD, Babcock J, Keitel W, El Sahly H, Poland GA, Jacobson RM, Keyserling HL, Semenova VA, Li H, Schiffer J, Dababneh H, Martin SK, Martin SW, Marano N, Messonnier NE, Quinn CP.

Vaccine. 2014 Feb 12;32(8):1019-28. doi: 10.1016/j.vaccine.2013.10.039. Epub 2013 Dec 25.

PMID:
24373307
14.

Geotemporal analysis of Neisseria meningitidis clones in the United States: 2000-2005.

Wiringa AE, Shutt KA, Marsh JW, Cohn AC, Messonnier NE, Zansky SM, Petit S, Farley MM, Gershman K, Lynfield R, Reingold A, Schaffner W, Thompson J, Brown ST, Lee BY, Harrison LH.

PLoS One. 2013 Dec 12;8(12):e82048. doi: 10.1371/journal.pone.0082048. eCollection 2013.

15.

Global epidemiology of invasive meningococcal disease.

Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, Zhujun S, Bhutta ZA, Abramson J.

Popul Health Metr. 2013 Sep 10;11(1):17. doi: 10.1186/1478-7954-11-17.

16.

Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States.

Mandal S, Wu HM, MacNeil JR, Machesky K, Garcia J, Plikaytis BD, Quinn K, King L, Schmink SE, Wang X, Mayer LW, Clark TA, Gaskell JR, Messonnier NE, DiOrio M, Cohn AC.

Clin Infect Dis. 2013 Aug;57(3):344-8. doi: 10.1093/cid/cit243. Epub 2013 Apr 17.

PMID:
23595832
17.

Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE; Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2013 Mar 22;62(RR-2):1-28.

18.

Waning immunity to pertussis following 5 doses of DTaP.

Tartof SY, Lewis M, Kenyon C, White K, Osborn A, Liko J, Zell E, Martin S, Messonnier NE, Clark TA, Skoff TH.

Pediatrics. 2013 Apr;131(4):e1047-52. doi: 10.1542/peds.2012-1928. Epub 2013 Mar 11.

PMID:
23478868
19.

Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010.

Misegades LK, Winter K, Harriman K, Talarico J, Messonnier NE, Clark TA, Martin SW.

JAMA. 2012 Nov 28;308(20):2126-32. doi: 10.1001/jama.2012.14939.

PMID:
23188029
20.

Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity.

Kristiansen PA, Diomandé F, Ba AK, Sanou I, Ouédraogo AS, Ouédraogo R, Sangaré L, Kandolo D, Aké F, Saga IM, Clark TA, Misegades L, Martin SW, Thomas JD, Tiendrebeogo SR, Hassan-King M, Djingarey MH, Messonnier NE, Préziosi MP, Laforce FM, Caugant DA.

Clin Infect Dis. 2013 Feb;56(3):354-63. doi: 10.1093/cid/cis892. Epub 2012 Oct 19.

PMID:
23087396
21.

Estimating the effectiveness of acellular pertussis vaccines.

Misegades LK, Martin SW, Messonnier NE, Clark TA.

Clin Infect Dis. 2012 Nov 15;55(10):1432-3; author reply 1435-6. doi: 10.1093/cid/cis669. Epub 2012 Aug 7. No abstract available.

PMID:
22871824
22.

Haemophilus influenzae type b disease and vaccine booster dose deferral, United States, 1998-2009.

Briere EC, Jackson M, Shah SG, Cohn AC, Anderson RD, MacNeil JR, Coronado FM, Mayer LW, Clark TA, Messonnier NE.

Pediatrics. 2012 Sep;130(3):414-20. doi: 10.1542/peds.2012-0266. Epub 2012 Aug 6.

23.

Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.

Novak RT, Kambou JL, Diomandé FV, Tarbangdo TF, Ouédraogo-Traoré R, Sangaré L, Lingani C, Martin SW, Hatcher C, Mayer LW, Laforce FM, Avokey F, Djingarey MH, Messonnier NE, Tiendrébéogo SR, Clark TA.

Lancet Infect Dis. 2012 Oct;12(10):757-64. doi: 10.1016/S1473-3099(12)70168-8. Epub 2012 Jul 18.

24.

Haemophilus haemolyticus isolates causing clinical disease.

Anderson R, Wang X, Briere EC, Katz LS, Cohn AC, Clark TA, Messonnier NE, Mayer LW.

J Clin Microbiol. 2012 Jul;50(7):2462-5. doi: 10.1128/JCM.06575-11. Epub 2012 May 9.

25.

Whole genome sequencing to investigate the emergence of clonal complex 23 Neisseria meningitidis serogroup Y disease in the United States.

Krauland MG, Dunning Hotopp JC, Riley DR, Daugherty SC, Marsh JW, Messonnier NE, Mayer LW, Tettelin H, Harrison LH.

PLoS One. 2012;7(4):e35699. doi: 10.1371/journal.pone.0035699. Epub 2012 Apr 27.

26.

Does tetanus-diphtheria-acellular pertussis vaccination interfere with serodiagnosis of pertussis infection?

Pawloski LC, Kirkland KB, Baughman AL, Martin MD, Talbot EA, Messonnier NE, Tondella ML.

Clin Vaccine Immunol. 2012 Jun;19(6):875-80. doi: 10.1128/CVI.05686-11. Epub 2012 Apr 25.

27.

Pertussis control: time for something new?

Clark TA, Messonnier NE, Hadler SC.

Trends Microbiol. 2012 May;20(5):211-3. doi: 10.1016/j.tim.2012.03.003. Epub 2012 Apr 9.

PMID:
22494804
28.

Inching toward a serogroup B meningococcal vaccine for infants.

Cohn AC, Messonnier NE.

JAMA. 2012 Feb 8;307(6):614-5. doi: 10.1001/jama.2012.118. No abstract available.

PMID:
22318284
29.

Modeling insights into Haemophilus influenzae type b disease, transmission, and vaccine programs.

Jackson ML, Rose CE, Cohn A, Coronado F, Clark TA, Wenger JD, Bulkow L, Bruce MG, Messonnier NE, Hennessy TW.

Emerg Infect Dis. 2012 Jan;18(1):13-20. doi: 10.3201/eid1801.110336.

30.

Pertussis Pseudo-outbreak linked to specimens contaminated by Bordetella pertussis DNA From clinic surfaces.

Mandal S, Tatti KM, Woods-Stout D, Cassiday PK, Faulkner AE, Griffith MM, Jackson ML, Pawloski LC, Wagner B, Barnes M, Cohn AC, Gershman KA, Messonnier NE, Clark TA, Tondella ML, Martin SW.

Pediatrics. 2012 Feb;129(2):e424-30. doi: 10.1542/peds.2011-1710. Epub 2012 Jan 16.

PMID:
22250029
31.

Early Impact of the US Tdap vaccination program on pertussis trends.

Skoff TH, Cohn AC, Clark TA, Messonnier NE, Martin SW.

Arch Pediatr Adolesc Med. 2012 Apr;166(4):344-9. doi: 10.1001/archpediatrics.2011.1093. Epub 2012 Jan 2.

PMID:
22213608
32.

Clinical validation of multiplex real-time PCR assays for detection of bacterial meningitis pathogens.

Wang X, Theodore MJ, Mair R, Trujillo-Lopez E, du Plessis M, Wolter N, Baughman AL, Hatcher C, Vuong J, Lott L, von Gottberg A, Sacchi C, McDonald JM, Messonnier NE, Mayer LW.

J Clin Microbiol. 2012 Mar;50(3):702-8. doi: 10.1128/JCM.06087-11. Epub 2011 Dec 14.

33.

Comparative study of different sources of pertussis toxin (PT) as coating antigens in IgG anti-PT enzyme-linked immunosorbent assays.

Kapasi A, Meade BD, Plikaytis B, Pawloski L, Martin MD, Yoder S, Rock MT, Coddens S, Haezebroeck V, Fievet-Groyne F, Bixler G, Jones C, Hildreth S, Edwards KM, Messonnier NE, Tondella ML.

Clin Vaccine Immunol. 2012 Jan;19(1):64-72. doi: 10.1128/CVI.05460-11. Epub 2011 Nov 23.

34.

Current epidemiology and trends in invasive Haemophilus influenzae disease--United States, 1989-2008.

MacNeil JR, Cohn AC, Farley M, Mair R, Baumbach J, Bennett N, Gershman K, Harrison LH, Lynfield R, Petit S, Reingold A, Schaffner W, Thomas A, Coronado F, Zell ER, Mayer LW, Clark TA, Messonnier NE.

Clin Infect Dis. 2011 Dec;53(12):1230-6. doi: 10.1093/cid/cir735.

PMID:
22080119
35.

Haemophilus influenzae type b carriage among young children in metropolitan Atlanta in the context of vaccine shortage and booster dose deferral.

Thomas JD, Jackson ML, Sharma D, Mair R, Bach MC, Castillo D, Ejigiri OG, Satola S, Cohn AC, Jerris R, Jain S, Farley MM, Mayer LW, Messonnier NE.

Clin Vaccine Immunol. 2011 Dec;18(12):2178-80. doi: 10.1128/CVI.05254-11. Epub 2011 Oct 19.

36.

Identifying host genetic risk factors in the context of public health surveillance for invasive pneumococcal disease.

Lingappa JR, Dumitrescu L, Zimmer SM, Lynfield R, McNicholl JM, Messonnier NE, Whitney CG, Crawford DC.

PLoS One. 2011;6(8):e23413. doi: 10.1371/journal.pone.0023413. Epub 2011 Aug 15.

37.

Bacterial meningitis in the United States, 1998-2007.

Thigpen MC, Whitney CG, Messonnier NE, Zell ER, Lynfield R, Hadler JL, Harrison LH, Farley MM, Reingold A, Bennett NM, Craig AS, Schaffner W, Thomas A, Lewis MM, Scallan E, Schuchat A; Emerging Infections Programs Network.

N Engl J Med. 2011 May 26;364(21):2016-25. doi: 10.1056/NEJMoa1005384.

38.

sodC-based real-time PCR for detection of Neisseria meningitidis.

Dolan Thomas J, Hatcher CP, Satterfield DA, Theodore MJ, Bach MC, Linscott KB, Zhao X, Wang X, Mair R, Schmink S, Arnold KE, Stephens DS, Harrison LH, Hollick RA, Andrade AL, Lamaro-Cardoso J, de Lemos AP, Gritzfeld J, Gordon S, Soysal A, Bakir M, Sharma D, Jain S, Satola SW, Messonnier NE, Mayer LW.

PLoS One. 2011 May 5;6(5):e19361. doi: 10.1371/journal.pone.0019361.

39.

Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States.

Wang X, Cohn A, Comanducci M, Andrew L, Zhao X, MacNeil JR, Schmink S, Muzzi A, Bambini S, Rappuoli R, Pizza M, Murphy E, Hoiseth SK, Jansen KU, Anderson AS, Harrison LH, Clark TA, Messonnier NE, Mayer LW.

Vaccine. 2011 Jun 24;29(29-30):4739-44. doi: 10.1016/j.vaccine.2011.04.092. Epub 2011 May 13.

PMID:
21571026
40.

Detection of bacterial pathogens in Mongolia meningitis surveillance with a new real-time PCR assay to detect Haemophilus influenzae.

Wang X, Mair R, Hatcher C, Theodore MJ, Edmond K, Wu HM, Harcourt BH, Carvalho Mda G, Pimenta F, Nymadawa P, Altantsetseg D, Kirsch M, Satola SW, Cohn A, Messonnier NE, Mayer LW.

Int J Med Microbiol. 2011 Apr;301(4):303-9. doi: 10.1016/j.ijmm.2010.11.004. Epub 2011 Jan 26.

PMID:
21276750
41.

Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine.

Macneil JR, Cohn AC, Zell ER, Schmink S, Miller E, Clark T, Messonnier NE; Active Bacterial Core surveillance (ABCs) Team and MeningNet Surveillance Partners.

Pediatr Infect Dis J. 2011 Jun;30(6):451-5. doi: 10.1097/INF.0b013e31820a8b3c.

PMID:
21206392
42.

Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005.

Harrison LH, Shutt KA, Schmink SE, Marsh JW, Harcourt BH, Wang X, Whitney AM, Stephens DS, Cohn AA, Messonnier NE, Mayer LW.

J Infect Dis. 2010 Apr 15;201(8):1208-24. doi: 10.1086/651505.

43.

Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease.

Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, Pondo T, Arnold KE, Baumbach J, Bennett N, Craig AS, Farley M, Gershman K, Petit S, Lynfield R, Reingold A, Schaffner W, Shutt KA, Zell ER, Mayer LW, Clark T, Stephens D, Messonnier NE.

Clin Infect Dis. 2010 Jan 15;50(2):184-91. doi: 10.1086/649209.

PMID:
20001736
44.

MCV vaccination in the presence of vaccine-associated Guillain-Barré Syndrome risk: a decision analysis approach.

Cho BH, Clark TA, Messonnier NE, Ortega-Sanchez IR, Weintraub E, Messonnier ML.

Vaccine. 2010 Jan 8;28(3):817-22. doi: 10.1016/j.vaccine.2009.10.050. Epub 2009 Oct 30.

PMID:
19879992
45.

Genotypic comparison of invasive Neisseria meningitidis serogroup Y isolates from the United States, South Africa, and Israel, isolated from 1999 through 2002.

Whitney AM, Coulson GB, von Gottberg A, Block C, Keller N, Mayer LW, Messonnier NE, Klugman KP.

J Clin Microbiol. 2009 Sep;47(9):2787-93. doi: 10.1128/JCM.00091-09. Epub 2009 Jul 1.

46.

Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005-2006.

Mutonga DM, Pimentel G, Muindi J, Nzioka C, Mutiso J, Klena JD, Morcos M, Ogaro T, Materu S, Tetteh C, Messonnier NE, Breiman RF, Feikin DR.

Am J Trop Med Hyg. 2009 Apr;80(4):619-24.

PMID:
19346388
47.

Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America.

Wu HM, Harcourt BH, Hatcher CP, Wei SC, Novak RT, Wang X, Juni BA, Glennen A, Boxrud DJ, Rainbow J, Schmink S, Mair RD, Theodore MJ, Sander MA, Miller TK, Kruger K, Cohn AC, Clark TA, Messonnier NE, Mayer LW, Lynfield R.

N Engl J Med. 2009 Feb 26;360(9):886-92. doi: 10.1056/NEJMoa0806414.

48.

Cost analysis of an integrated disease surveillance and response system: case of Burkina Faso, Eritrea, and Mali.

Somda ZC, Meltzer MI, Perry HN, Messonnier NE, Abdulmumini U, Mebrahtu G, Sacko M, Touré K, Ki SO, Okorosobo T, Alemu W, Sow I.

Cost Eff Resour Alloc. 2009 Jan 8;7:1. doi: 10.1186/1478-7547-7-1.

49.

Integrating host genomics with surveillance for invasive bacterial diseases.

Crawford DC, Zimmer SM, Morin CA, Messonnier NE, Lynfield R, Yi Q, Shephard C, Wong M, Rieder MJ, Livingston RJ, Nickerson DA, Whitney CG, Lingappa J.

Emerg Infect Dis. 2008 Jul;14(7):1138-40. doi: 10.3201/eid1407.071287.

50.

Risk factors for meningococcal disease in students in grades 9-12.

Harrison LH, Kreiner CJ, Shutt KA, Messonnier NE, O'Leary M, Stefonek KR, Lin H, Lynfield R, Barrett NL, Arnold KE, Jones TF, Montero JT; Meningococcal High School Study Group.

Pediatr Infect Dis J. 2008 Mar;27(3):193-9. doi: 10.1097/INF.0b013e31815c1b3a.

PMID:
18277925

Supplemental Content

Loading ...
Support Center